

**YERVOY®**

(ipilimumab)


# Patient Card

This Patient Card fulfills the conditions of the marketing authorisation and has been approved by the Health Products Regulatory Authority (HPRA).

Date of HPRA Approval: 19 Aug 2025

Local Approval Number: 731-IE-2500002

Date of Preparation: Aug 2025



## IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY (ipilimumab) alone.



Ipilimumab treatment may increase the risk of serious or even life-threatening immune-related side effects, which may affect different parts of the body. If you have any signs or symptoms, tell your doctor right away.

## POSSIBLE SIDE EFFECTS



Bowel and stomach

Diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools, more frequent bowel movements than usual, pain or tenderness in your stomach or abdomen area, nausea or vomiting



Eye

Redness in the eye, pain in the eye, vision problems or blurry vision



Hormone glands

Rapid heartbeat, increased sweating, weight gain or loss, feeling cold, hair loss, constipation, your voice gets deeper, fever, tiredness, headache, dizziness or fainting, feeling more hungry or thirsty than usual, needing to urinate more often, or behavioural changes (e.g. less sex drive, being irritable or forgetful)



Liver

Eye or skin yellowing (jaundice), pain on the right side of your stomach area, dark urine, or bleeding



Lungs

Shortness of breath, cough or chest pain



Nerves

Muscle weakness, numbness or tingling in legs, arms or face, dizziness, loss of consciousness or difficulty waking up



Skin

Skin rash with or without itching, dry skin, blisters and/or peeling of the skin, mouth sores, swelling of the face or lymph glands

## Other important side effects:

Severe infusion reactions:

- Reactions to infusing ipilimumab into the bloodstream might occur, usually during or within 24 hours of receiving a dose.
- Tell your doctor or nurse right away if you get these symptoms during an infusion of ipilimumab: chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, and feeling like passing out.

IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the ipilimumab Package Leaflet at [www.medicines.ie](http://www.medicines.ie) or contact Medical Information on 1 800 749 749 or [medical.information@bms.com](mailto:medical.information@bms.com).

IMPORTANT Information for Healthcare Professionals

- This patient is treated with ipilimumab monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the ipilimumab Summary of Product Characteristics (SmPC) at [www.medicines.ie](http://www.medicines.ie) or contact Medical Information on 1 800 749 749 or [medical.information@bms.com](mailto:medical.information@bms.com) for more information.

The healthcare professional treating this patient with ipilimumab should complete the ‘My Doctor’s Contact Information’ section of this Patient Card.

My Doctor’s Contact Information

(who prescribed ipilimumab)

Name of Doctor: \_\_\_\_\_

Office Phone: \_\_\_\_\_

After-Hours Phone: \_\_\_\_\_

My Contact Information

My Name and Phone: \_\_\_\_\_

Caregiver Name and Phone (in case of emergency):  
\_\_\_\_\_

**Reporting of side effects:** If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via HPRA Pharmacovigilance at [www.hpra.ie](http://www.hpra.ie). By reporting side effects, you can help provide more information on the safety of this medicine. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or [medical.information@bms.com](mailto:medical.information@bms.com).